BioAtla Inc (NASDAQ:BCAB) currently has a daily average trading volume of 485.04K but it saw 1496153 shares traded in last market. With a market cap of 187.38M USD, the company’s current market price of $3.92 came rising about 5.95 while comparing to the previous closing price of $3.70. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.07 and as low as $1.24.
Taking a look at 20-day trading activity of BioAtla Inc (BCAB) gives us an average price of $2.86, while its current price level is -3.64% below from 52-week high level whereas it is 216.13% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.63 while that of 200 days or SMA-200 reads an average of $2.33. A closer look into the stock’s movement over the week reveals that its volatility is standing at 12.30% during that period while stretching the period over a month that decreases to 10.20%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 75.54 which implies that the stock is in overbought territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the JMP Securities which initiated the stock as “Mkt Outperform” in its note to investors issued on September 15, 2022, recommending a price target of $17 for it. Credit Suisse downgraded its recommendation for the stock as a “Neutral” from “Outperform” on May 05, 2022 while assigning a price target range of $35-$5. H.C. Wainwright also issued its recommendations for the stock as it initiated the price target for the stock is $25.
Over the week, BCAB’s stock price is moving 13.29% up while it is 41.52% when we observe its performance for the past one month. Year-to-date it is 59.35% up and over the past year, the stock is showing an upside performance of 38.52%.
The latest quarterly earnings report issued by the company was for quarter ended 9/29/2023, when its quarterly earnings per share (EPS) of -$0.7 beat the consensus estimate of -$0.8 for the same. For BCAB, analysts are forecasting an EPS-growth rate of -0.70% for current year and estimate for EPS growth in next year is 30.10%.
Currently, BioAtla Inc’s total number of outstanding shares is 48.08M with 9.69% of that held by the insiders while 64.79% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -172.65% and return on equity (ROE) at -98.37%. Stock’s beta reads 1.04. Stock has a price to book (P/B) ratio of 2.67. Its return on asset (ROA) is -71.49% on average.
